Utility-Based Dose Selection for Phase II Dose-Finding Studies
Authors:
- 13 April 2021
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 55 (4) , 818-840
Abstract
Background and Objectives Dose selection is a key feature of clinical development. Poor dose selection has been recognized as a major driver of development failure in late phase. It usually involves both efficacy and safety criteria. The objective of this paper is to develop and implement a novel fully Bayesian statistical framework to optimize the dose selection process by maximizing the expected utility in phase III. Methods The success probability is characterized by means of a utility function with two components, one for efficacy and one for safety. Each component refers to a dose-response model. Moreover, a sequential design (with futility and efficacy rules at the interim analysis) is compared to a fixed design in order to allow one to hasten the decision to perform the late phase study. Operating characteristics of this approach are extensively assessed by simulations under a wide range of dose-response scenarios. Results and Conclusions Simulation results illustrate the difficulty of simultaneously estimating two complex dose-response models with enough accuracy to properly rank doses using an utility function combining the two. The probability of making the good decision increases with the sample size. For some scenarios, the sequential design has good properties: with a quite large probability of study termination at interim analysis, it enables to reduce the sample size while maintaining the properties of the fixed design.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spotStatistics in Medicine, 2015
- Meta-Analysis of Clinical Dose–Response in a Large Drug Development PortfolioStatistics in Biopharmaceutical Research, 2014
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012JAMA, 2014
- Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase IIIStatistics in Biopharmaceutical Research, 2010
- Optimal Designs for Estimating the Interesting Part of a Dose-Effect CurveJournal of Biopharmaceutical Statistics, 2007
- Adaptive designs for dose-finding based on efficacy–toxicity responseJournal of Statistical Planning and Inference, 2006
- Combining Multiple Comparisons and Modeling Techniques in Dose‐Response StudiesBiometrics, 2005
- The Delphi ListJournal of Clinical Epidemiology, 1998
- An Implementation of the Batch Means MethodINFORMS Journal on Computing, 1997
- Geometric convergence and central limit theorems for multidimensional Hastings and Metropolis algorithmsBiometrika, 1996